Background: Although the diagnosis of chondrosarcoma, especially the distinction between enchondroma and low-grade chondrosarcoma or low-grade chondrosarcoma and high-grade chondrosarcoma, is pathologically difficult, differential diagnosis is very important because the treatment strategies for these diseases are completely different. The grading system is crucial in predicting biologic behavior and prognosis, however, exact pathological grading is difficult using only routine examinations because the criteria of the grading system are not necessarily definitive. Growth arrest and DNA damage-inducible protein 45β (GADD45β) is an essential molecule for chondrocytes during terminal differentiation. In the present study, we investigated the immunohistochemical expression of GADD45β in enchondroma, and chondrosarcoma of histological grades I, II, and III, to clarify the diagnostic significance of GADD45β in pathological grading of chondrosarcoma.

Methods: Twenty samples (enchondroma = 6, chondrosarcoma grade I = 7, grade II = 6, grade III = 1) were used for immunohistochemical analysis to investigate the expression of GADD45β. Quantitative analysis was performed to compare the number of GADD45β positive cells and pathological grading.

Results: Over 70% of the cells in enchondromas expressed GADD45β. On the other hand, the expression of GADD45β decreased significantly according to the histological grade of chondrosarcoma (grade I: 45%; grade II: 13.8%; and grade III: 3.8%).

Conclusions: The association of GADD45β expression and pathological grading of chondrosarcoma in the present study suggests that the immunohistochemical study of GADD45β may be a specific diagnostic parameter for chondrosarcoma cell differentiation.
Approximately 62% of the patients are in the fourth to sixth decades. More than two-thirds of the tumors are in the trunk, including the pelvis, ribs, and shoulder girdle. The pathological grading of chondrosarcoma is based on cellularity, nuclear atypia, and pleomorphism [5]; however, in some borderline cases, exact histological grading is difficult using only routine histopathological examinations because the criteria of the grading system are not necessarily definitive [6]. Therefore, correlative interpretation of histopathological, imaging, and clinical information is currently used for making this distinction.

Several authors have reported supplementary methods, including the evaluation of DNA synthesis and content [7,8], flow cytometry [9], p53 [10], MIB-1 [11], COX-2 [6], and p21 [3], to assess the prognosis of patients with chondrosarcoma. These methods are, however, based on non-specific phenomena in chondrocytic differentiation.

Chondrogenesis, i.e., cartilage formation including chondrocyte differentiation and maturation, is a process that occurs during skeletal development. This process occurs in stages beginning with mesenchymal cell recruitment and migration, proliferation, and condensation, followed by chondroprogenitor cell determination and differentiation. Finally, chondrocyte differentiation is terminated by hypertrophy. Bone morphogenetic proteins (BMPs), which were originally identified as molecules that induce ectopic endochondral ossification [12], set the stage for bone morphogenesis by initiating chondroprogenitor cell determination and differentiation and regulate the later stages of chondrocyte maturation and hypertrophic phenotype [13].

We previously reported the growth arrest and DNA damage-inducible protein 45β (GADD45β) as an early responding gene to BMP-2 stimulation in the chondrocyte cell line [14]. The expression of GADD45β gradually increased along with chondrocyte differentiation from the proliferation phase to hypertrophic phase. GADD45β stimulates MMP-13 (a marker of terminal differentiation of hypertrophic chondrocytes) promoter activity in chondrocytes through the JNK-mediated phosphorylation of JunD, partnered with Fra2 and in synergy with Runx2. These facts suggested that GADD45β plays an essential role during chondrocyte terminal differentiation.

In the present study, we investigated the immunohistochemical expression of GADD45β in enchondroma and chondrosarcoma of histological grades I, II, and III, to clarify the diagnostic significance of GADD45β in histological grading of chondrosarcoma.

**Methods**

**Study samples**

Formalin-fixed, paraffin-embedded tissues collected between 1978 and 2009 were obtained from the Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University upon approval of the ethics committee. The characteristics of the patients are summarized in Table 1.

**Pathological review and grading**

Histological slides of the tumors from all the patients were reviewed by 2 or 3 pathologists. The histological diagnosis was based on the textbook definition [15]. The histological grade of the chondrosarcomas was determined on the basis of the nuclear size, nuclear staining (hyperchromasia), and cellularity according to the World Health Organization Classification of Bone Tumors (2002) [15].

**Immunohistochemical analysis**

The immunohistochemical analysis was performed using the labeled streptavidin-biotin method using goat polyclonal anti-human GADD45β (C-18; 1:1000) antibody (Santa Cruz Biotechnology, Inc. CA, USA). The results were evaluated by 2 investigators, who were unaware of the pathological grading of the samples. We calculated the proportion of stained tumor cells after performing nuclear staining.

Quantitative analysis of the GADD45β immunoreactive cells was performed. The immunostained sections were photographed at 100× magnification with a microscope, and the GADD45β immunoreactive cells and non-positive cells were counted in 4 fields. We

| Case | Sex/Age | Location | Pathology & Grade | GADD45b positivity (%) |
|------|---------|----------|------------------|------------------------|
| 1    | ♂/43   | Femur    | Enchondroma       | 68.9                   |
| 2    | ♂/16   | Metatarsal| Enchondroma       | 81.6                   |
| 3    | ♀/46   | Phalanx  | Enchondroma       | 74.4                   |
| 4    | ♂/32   | Phalanx  | Enchondroma       | 83.5                   |
| 5    | ♀/58   | Femur    | Enchondroma       | 66.6                   |
| 6    | ♀/54   | Phalanx  | Enchondroma       | 68.8                   |
| 7    | ♀/52   | Femur    | CSA grade I       | 67.3                   |
| 8    | ♀/39   | Pelvis   | CSA grade I       | 55.5                   |
| 9    | ♀/46   | Femur    | CSA grade I       | 44.6                   |
| 10   | ♂/61   | Femur    | CSA grade I       | 49.2                   |
| 11   | ♂/18   | Tibia    | CSA grade I       | 29.8                   |
| 12   | ♂/67   | Mandible | CSA grade I       | 38.1                   |
| 13   | ♀/32   | Pelvis   | CSA grade I       | 31.0                   |
| 14   | ♀/50   | Femur    | CSA grade II      | 11.8                   |
| 15   | ♀/64   | Rib      | CSA grade II      | 3.9                    |
| 16   | ♀/72   | Femur    | CSA grade II      | 14.8                   |
| 17   | ♀/55   | Pelvis   | CSA grade II      | 5.9                    |
| 18   | ♂/44   | Femur    | CSA grade II      | 11.9                   |
| 19   | ♂/67   | Mandible | CSA grade II      | 34.0                   |
| 20   | ♂/61   | Mandible | CSA grade III     | 3.8                    |
calculated the percentages of GADD45β positive cells. Statistical comparisons in each grade (enchondroma, grade I and II) were performed by a one-way ANOVA using Stat-View version 5.0. If significance was achieved, a post-hoc Fisher’s protected least significant differences (PLSD) test was performed to determine whether significant differences existed. Significance was set at p < 0.05.

Results
The patient data and lesion characteristics are listed in Table 1. There were 6 cases of enchondroma and 14 of chondrosarcoma, including 7 with grade I, 6 with grade II, and 1 with grade III. Enchondromas, on average, showed 74% reactivity for GADD45β (68.9-83.5%). In the case of chondrosarcomas, the percentage of GADD45β positive cells was inversely proportional to the tumor grade. GADD45β was expressed in 45% (29.8-67.3%) of the cells in grade I chondrosarcoma and 13.8% (1.2-34.1%) of cells in grade II. There were statistically significant differences among the three groups except grade III chondrosarcoma. (Fig. 1)

In grade II chondrosarcomas, comparatively mature cells, which had plump nuclei and were surrounded by cartilage matrix, were positive for GADD45β. In contrast, most of the atypical spindle cells, which had enlarged hyperchromatic nuclei and myxomatous matrix, were negative. (Fig. 2C) Although we had only 1 case of grade III chondrosarcoma, only 3.8% of the cells were positive for GADD45β.

Discussion
The pathological grade of chondrosarcomas is considered to be the most useful predictor of the clinical outcome and course of the treatment for these tumors. While criteria for pathological grade of chondrosarcomas have been published, the application of these criteria is difficult and requires expert judgement [16].

Figure 1 Percentages of GADD45β positive cells

![Figure 1 Percentages of GADD45β positive cells](image)

Figure 2 Immunohistochemical staining for GADD45β

A) Enchondroma, B) Grade I Chondrosarcoma, C) Grade II Chondrosarcoma, D) Grade III Chondrosarcoma

Chondrocytes which have plump nuclei and are surrounded by cartilage matrix, are positive for GADD45β. In contrast, most of the atypical and immature cells in grade II or III chondrosarcoma are negative. Over 70% of the cells in enchondromas expressed GADD45β. In chondrosarcomas, the rate of GADD45β positive cells was inversely proportional to its grade. There were statistically significant differences among three groups except grade III chondrosarcoma. (*: P < 0.01).
Therefore, correlative interpretation of histopathological, imaging, and clinical information is currently used as a method to provide the appropriate prognostic information. Recently, the reliability of histopathological and radiological grading of cartilaginous neoplasms in long bones was studied by 9 recognized musculoskeletal pathologists and 8 recognized musculoskeletal radiologists [17]. They reviewed 49 consecutive cases of cartilaginous lesions in long bones and estimated the interobserver reliability for the grading of cartilaginous neoplasms in long bones to be 0.443 for pathologists and 0.345 for radiologists. These data demonstrate that the interpretation of histopathological features from cartilaginous lesions has some limits. These data encouraged the efforts to develop better prospective pathological interpretation algorithms or better prospective imaging protocols.

The present study provides the first immunohistochemical evidence that GADD45β expression is significantly associated with the grading of chondrosarcomas. GADD45β is a member of the GADD45 family of small (18 kDa) proteins, which are known to be associated with cell growth control, apoptotic cell death, and the cellular response to DNA damage [18]. Initially, GADD45β encoded by MyD118 was identified as a myeloid differentiation primary response gene activated by IL-6 in murine myeloid leukemia cells upon induction of terminal differentiation [19].

Formation of the vertebral skeleton through endochondral ossification is a physiological process, which involves progressive differentiation of proliferating chondrocytes to growth-arrested hypertrophic chondrocytes. Interestingly, the GADD45β protein localized prominently in the nucleus of the late-stage hypertrophic chondrocytes, but not of the proliferating chondrocytes. Although GADD45β is an abundant protein in chondrocytes, overexpression of GADD45β in terminally differentiated chondrocytes in the growth plate promotes JNK and p38 signaling cascades to regulate both MMP-13 and Col10a1 expression, which are crucial for the maintenance of the terminal differentiated phenotype [20]. Therefore, the association of GADD45β expression and pathological grading of chondrosarcoma in the present study suggests that immunohistochemical study of GADD45β may be a specific diagnostic parameter for chondrosarcoma cell differentiation.

In this study, there was overlap in the proportion of GADD45β-expressing cells between enchondroma and grade I chondrosarcoma (CSA), as shown for Case 7, and between grade I CSA and grade II CSA, as shown for Case 19. The limitation of this pilot study of GADD45β expression in chondrogenic tumors was the small number of subjects. Therefore, the study should be conducted on a larger number of subjects to determine whether the number of such “overlap” cases would increase.

Conclusions
In conclusion, our data suggests that immunohistochemical study of GADD45β provides valuable prognostic information and facilitates examination of histological grading. More studies involving larger number of patients must be performed to further characterize its potential diagnostic validity.

Acknowledgements
This research was supported by KAKENHI-20591787(0).

Author details
1Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 2Molecular and Cellular Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 3School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.

Authors’ contributions
ZM, AT, MY, SN carried out the immunohistochemical study. TY, YI participated in the design of the study, and SH contributed in the statistical analysis. SK and KI conceived the study and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 30 August 2010 Accepted: 13 October 2010
Published: 13 October 2010

References
1. Larsson SE, Lorentzon R: The incidence of malignant primary bone tumours in relation to age, sex and site. A study of osteogenic sarcoma, chondrosarcoma, and Ewing’s sarcoma diagnosed in Sweden from 1958 to 1968. J Bone Joint Surg Br 1974, 56:534-540.
2. Hartley AL, Blair V, Harris M, Birch JM, Banerjee SS, Freemont AJ, McClure J, McWilliam LJ: Sarcomas in north west England:II. Incidence. Br J Cancer 1991, 64:1145-1150.
3. Hiraoka K, Zenmyo M, Komiya S, Kawabata R, Yokouchi M, Suzuki R, Hamada T, Kato S, Nagata K: Relationship of p21(waf1/cip1) and differentiation on chondrosarcoma cells. Virchows Arch 2002, 440:285-290.
4. Unni KK: General aspects and data on 11,087 cases. In Dahlin’s bone tumor Edited by: Lippincott-Raven, Minnesota . Fifth. 1996, 25.
5. Bentori HD, Czerniak B: Malignant cartilage tumours. Bone tumors (Ma). Mosby, St Louis 1998, 353-440.
6. Endo M, Matsumura T, Yamauchi T: Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcoma. Human pathology 2006, 37:471-476.
7. Alho A, Skjeldal S, Melvik JE, Pettersen EO, Larsen TE: The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumours. Anticancer Res 1993, 13:2383-2387.
8. Krechbergs A, Boquist L, Borsén B, Larsson SE: Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features. Cancer 1982, 50:577-583.
9. Alho A, Connor JF, Mankin HJ, Schiller AL, Campbell CJ: Assessment of malignancy of cartilage tumours using flow cytometry. A preliminary report. J Bone Joint Surg Am 1983, 65:779-785.
10. Dobashi Y, Sugimura H, Sato A, Hirabayashi T, Kanda H, Kitagawa T, Kavaguchi N, Imamura T, Machinami R: Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagn Mol Pathol 1993, 2:257-263.
11. Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, Funai H, Uchida A: Prognostic significance of K67/MB-1 proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer 1996, 69:86-9.
12. Urist MR: Bone: Formation by autoinduction. Science 1965, 150:893-899.
13. Goldring MB, Tsuchimochi K, Ijiri K: The control of chondrogenesis. J Cellular Biochem 2006, 97:33-44.
14. Ijiri K, Zerbini LF, Peng H, Corea RG, Lu B, Walsh N, Zhao Y, Taniguchi N, Huang XL, Otu H, Wang H, Wang JF, Korniya S, Duy C, Rahman MU, Flavell RA, Gravallese EM, Oettgen P, Libermann TA, Goldring MB: A novel role for Gadd45b as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. J Biol Chem 2005, 280:38544-38554.
15. Bertoni F, Bacchini P, Hogendoorn PCW: Chondrosarcoma. In World health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. IARC Press, Lyon; 2002:247-251.
16. Murphey MD, Flemming DJ, Boyea SR, Bojesclu JA, Sweet DE, Temple HT: Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features. Radiographics 1998, 18:1213-1237.
17. Skeletal lesions interobserver correlation among expert diagnosticians study group: Reliability of histopathological and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am 2007, 89:2113-2123.
18. Amanullah A, Azam N, Balliet A, Hollander C, Hoffman B, Fornace A, Liebermann D: Cell signalling: cell survival and a Gadd45-factor deficiency. Nature 2003, 424:741-742.
19. Selvakumaran M, Lin HK, Sjin RT, Reed JC, Liebermann DA, Hoffman B: The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol 1994, 14:2352-2360.
20. Tsuchimochi K, Otero M, Dragomir CL, Plumb DA, Zerbini LF, Libermann TA, Marcu KB, Korniya S, Ijiri K, Goldring MB: Gadd45beta enhances Col10a1 transcription via the MTK1/MMK3/6/p38 axis and activation of C/EBPbeta-TAD4 in terminally differentiating chondrocytes. J Biol Chem 2010, 285:8395-8407.